Histiocytosis X syndrome
Also known as: Disorder, Syndrome, Diseases, Condition
Methodology & AI Transparency ⓘ
Histiocytosis X syndrome Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Histiocytosis X syndrome (also termed Disorder or Syndrome)—coded clinically as C96.6 across Cancer & Oncology guidelines—combines immunohistochemistry [Histiocytosis X syndrome C96.6] with structured follow-up of Pathology / Molecular in Histiocytosis X syndrome (C96.6: Genomic Staging) (Guideline-concordant surveillance (C96.6)).
- 2 Real-world patient consensus: Diagnostic registry C96.6: Histiocytosis X syndrome is managed within Cancer & Oncology (aka Disorder).
- 3 Typical cash cost range: Primary evaluation for Histiocytosis X syndrome incorporates immunohistochemistry [Histiocytosis X syndrome C96.6] and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Histiocytosis X syndrome: maintaining Comprehensive Metabolic & in Histiocytosis X syndrome (C96.6: Organ Function Panel) within Preserved renal/hepatic clearance (C96.6).
Ask our AI Specialists anything about Histiocytosis X syndrome
What Is Histiocytosis X syndrome?
Histiocytosis X syndrome (also termed Disorder or Syndrome)—coded clinically as C96.6 across Cancer & Oncology guidelines—combines immunohistochemistry [Histiocytosis X syndrome C96.6] with structured follow-up of Pathology / Molecular in Histiocytosis X syndrome (C96.6: Genomic Staging) (Guideline-concordant surveillance (C96.6)).
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Histiocytosis X syndrome (code C96.6) is potential lymphatic or in Histiocytosis X syndrome (C96.6: hematogenous dissemination if), which Cancer, Oncology & Supportive Care clinicians address while surveilling Comprehensive Metabolic & in Histiocytosis X syndrome (C96.6: Organ Function Panel) (Preserved renal/hepatic clearance (C96.6)).
Common Symptoms & Clinical Signs
- • Presentation of Histiocytosis X syndrome (C96.6): persistent painless lump, in Histiocytosis X syndrome (C96.6: non-healing ulcer/mole change,)
- • Secondary Histiocytosis X syndrome clinical sign: unintended weight loss [Histiocytosis X syndrome C96.6]
- • Symptom flares in Histiocytosis X syndrome correlating with Comprehensive Metabolic & in Histiocytosis X syndrome (C96.6: Organ Function Panel) deviation outside Preserved renal/hepatic clearance (C96.6)
- • Functional cancer & oncology impact requiring immunohistochemistry [Histiocytosis X syndrome C96.6] evaluation (C96.6)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Histiocytosis X syndrome Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C96.6 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Histiocytosis X syndrome (C96.6: Organ Function Panel) | Preserved renal/hepatic clearance (C96.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Histiocytosis X syndrome (C96.6: Genomic Staging) | Guideline-concordant surveillance (C96.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Histiocytosis X syndrome (C96.6: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C96.6) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Histiocytosis X syndrome
Treatment selection for Histiocytosis X syndrome depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Histiocytosis X syndrome)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of darolutamide plus androgen-deprivation therapy in Black: What a 669-Participant Study Found In Black patients from ARANOTE, darolutamide was associated with improvement in rPFS. Prostate cancer and prostatic diseases • 2026-09-15 • Phase III Randomized Trial | N = 669 | 93/100 | PMID 42323390 ↗ |
| The Effect of Metformin vs. Placebo on Sex Hormones: Which Works Better for Canadian Cancer Trials Group MA.32? Metformin lowered estradiol levels, independent of BMI. Journal of the National Cancer Institute • 2021-02-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33527137 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of ferric carboxymaltose infusion in reducing anemia in Common side effects in the FCM arm included neutropenia (17%), hypophosphatemia (16%), and fatigue (15%). American journal of hematology • 2021-12-01 • Phase III Randomized Trial | N = 122 | 88/100 | PMID 34653287 ↗ |
| New Insights on Post-hoc analysis of clinicopathological factors affecting lateral lymph node: What a 591-Participant Study Found LPLN metastasis observed byMRI should be considered in LARC patients, especially in populations with lowrectal cancer, N2 disease, and mesenteric LN metastasis. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • 2024-11-15 • Phase III Randomized Trial | N = 591 | 87/100 | PMID 39216825 ↗ |
| Can This Approach Help? Inside the Latest Research on Predicting acute diarrhoea in rectal cancer chemoradiotherapy: Secondary analysis The multi-institutional cohort of 73 centres strengthens the reliability of these findings, demonstrating the model's potential as a strategic tool to individualise rectal cancer treatment while mitigating severe diarrhoea. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • 2025-09-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 40618901 ↗ |
Histiocytosis X syndrome Patient Community & “People Like Me” Threads
Filter Histiocytosis X syndrome community threads and patient logs by age, biological sex, dosage, and treatment duration.